China's Venus Medtech Buys Rights to Next-Gen Cardiac Valve from Transcatheter of Germany

Venus Medtech, a Hangzhou cardiac device maker, bought a portfolio of cardiac valve technology from Transcatheter Technologies GmbH of Germany. The Transcatheter system allows the surgeon to reposition the valve once it is implanted, a unique feature. Using the technology, Venus will develop and market a third-gen valve system for use in China and the world. Venus' transcatheter aortic valve is currently awaiting CFDA approval. Terms of the agreement were not disclosed. More details.... Share this with colleagues: // //